Cardinal Health Beats Q3 Estimates, Raises Outlook—Stock Jumps in Pre-Market
Cardinal Health Inc (NYSE:CAH) delivered a stronger-than-expected third quarter for fiscal year 2026, prompting management to raise its full-year guidance. The report sent shares climbing in pre-market trading as investors responded favorably to the earnings beat and improved outlook.
Earnings Recap: Revenue Slightly Light, But Profit Beats Big
For the quarter ending March 31, 2026, Cardinal Health reported revenue of $60.9 billion, an 11% increase year-over-year. While that growth was robust, it came in just below the analyst consensus estimate of $62.29 billion, representing a modest miss on the top line.
Earnings per share (non-GAAP), however, painted a different picture. The company posted adjusted EPS of $3.17, well ahead of the $2.82 that analysts had expected—a beat of more than 12%. This bottom-line outperformance appears to have been the more significant driver for investors.
Key Highlights from the Press Release
- Revenue growth of 11% year-over-year to $60.9 billion.
- Non-GAAP EPS of $3.17, crushing estimates by $0.35.
- Full-year fiscal 2026 outlook raised, signaling confidence in the business trajectory.
Revenue vs. Estimates: Understanding the Disconnect
The top-line miss warrants some context. Cardinal Health’s Pharmaceutical and Specialty Solutions segment continues to generate strong revenue growth, buoyed by pharmaceutical distribution and specialty services. However, the broader market had baked in slightly higher expectations. The Global Medical Products and Distribution segment may have faced headwinds, though the company did not break out segment details in the initial release.
What matters more here is that the revenue miss was marginal, while the EPS beat was substantial. In healthcare distribution, margins often carry more weight than raw revenue numbers, and the ability to convert sales into profit more efficiently than expected is a clear positive signal.
Outlook Revised Higher
Cardinal Health raised its full-year fiscal 2026 guidance. Analysts had projected full-year sales of $261.2 billion and full-year earnings of $10.41 per share. By lifting the outlook, management is signaling that the underlying business is performing better than previously anticipated, particularly on profitability. This revision likely contributed to the positive market reaction, as it suggests the current quarter’s strength is not a one-off event.
Market Reaction: Pre-Market Rally
The stock is up approximately 1.6% in pre-market trading, following a flat weekly performance and a decline of roughly 4% over the past month. The modest pre-market gain suggests cautious optimism rather than euphoria. The recent weakness may have set a lower bar for the news to clear, and the earnings beat and raised guidance appear to have done exactly that.
Longer-term, the stock has been trading in a range, and this quarter could provide a catalyst for renewed momentum if investors see the EPS beat and guidance raise as evidence of operational improvement.
Analyst Expectations for Q4 and Beyond
Looking ahead, analysts expect Q4 fiscal 2026 revenue of $66.9 billion and EPS of $2.36. The full-year sales forecast of $261.2 billion implies continued strength in the pharmaceutical distribution business. Whether Cardinal Health can sustain its margin expansion will be key to hitting the raised guidance and exceeding these forward estimates.
For a deeper dive into historical earnings and future projections, including consensus estimates and analyst ratings, visit the CAH earnings page and CAH analyst forecasts page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making any investment decisions.